DDOX Emerges as Multi-Target Parkinson’s Therapy Candidate
A modified tetracycline compound called DDOX demonstrates remarkable multi-target effects against Parkinson’s disease pathology. The non-antibiotic derivative prevents cellular uptake of toxic protein fibrils while addressing multiple aspects of disease progression.
